Confronto
CagriSema vs. Tirzepatide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
nessun dato
2023788-19-2
Peso molecolare
nessun dato
4813 g/mol
Emivita
nessun dato
116 h
Sequenza
nessun dato
YXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSMeccanismo d'azione
CagriSema
CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
1
4
di cui sull'uomo
1
4
Effetti registrati
2
4
Contraddizioni aperte
0
1
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between CagriSema and Tirzepatide?
- CagriSema is classified as "Metabolico", while Tirzepatide is classified as "Metabolico". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Tirzepatide: Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CagriSema or Tirzepatide?
- The highest available evidence level is "RCT sull'uomo" for CagriSema and "RCT sull'uomo" for Tirzepatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CagriSema and Tirzepatide in Germany and the United States?
- Germania: CagriSema — Non approvato, Tirzepatide — Su prescrizione. Stati Uniti: CagriSema — Non approvato, Tirzepatide — Su prescrizione. These are factual summaries with source and review date on the individual pages.